Hi VacreI have worked for MVP on early new whistle design and...

Hi Vacre
I have worked for MVP on early new whistle design and don't hold due to conflicts. That said I can tell you that there is a lot of IP in the delivery system. The flow profile of the methoxyflurane inhalant is part of the efficacy as validated for the intended use for FDA and EU MDR reviews. This is why the new device took a while to get approved as the company had to prove it was equivalent clinically. The design of the whistle is carefully tuned to get the evaporation and flow rate profile right. Too fast and the dose is too high and the effect thins out quickly. Too slow and it is not effective and hard for the user to suck in. There are other key elements as well that have been improved and all patented.
The continuous flow processing is valuable not just for Penthrox but can be applied to other similar property drug production. That is a longer term goal I believe.